These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31935288)

  • 1. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.
    Liu X; Chen JG; Munshi M; Hunter ZR; Xu L; Kofides A; Tsakmaklis N; Demos MG; Guerrera ML; Chan GG; Jimenez C; Patterson CJ; Meid K; Keezer A; Castillo JJ; Treon SP; Yang G
    Blood Adv; 2020 Jan; 4(1):141-153. PubMed ID: 31935288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
    Munshi M; Liu X; Kofides A; Tsakmaklis N; Guerrera ML; Hunter ZR; Palomba ML; Argyropoulos KV; Patterson CJ; Canning AG; Meid K; Gustine J; Branagan AR; Flynn CA; Sarosiek S; Castillo JJ; Wang J; Buhrlage SJ; Gray NS; Munshi NC; Anderson KC; Treon SP; Yang G
    Blood Adv; 2022 Jun; 6(11):3332-3338. PubMed ID: 35255496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
    Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
    Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
    Munshi M; Liu X; Chen JG; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Jimenez C; Chan GG; Hunter ZR; Palomba ML; Argyropoulos KV; Meid K; Keezer A; Gustine J; Dubeau T; Castillo JJ; Patterson CJ; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
    Blood Cancer J; 2020 Jan; 10(1):12. PubMed ID: 32005797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
    Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of Non-Canonical, Inhibitory
    Cardona Gloria Y; Bernhart SH; Fillinger S; Wolz OO; Dickhöfer S; Admard J; Ossowski S; Nahnsen S; Siebert R; Weber ANR
    Front Immunol; 2021; 12():616451. PubMed ID: 34163463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.
    Minderman M; Lantermans H; van der Zwaan C; Hoogendijk AJ; van den Biggelaar M; Kersten MJ; Spaargaren M; Pals ST
    Blood Cancer J; 2023 Aug; 13(1):125. PubMed ID: 37591861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
    Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
    Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
    Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
    Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.
    Lantermans HC; Minderman M; Kuil A; Kersten MJ; Pals ST; Spaargaren M
    Leukemia; 2021 Mar; 35(3):881-886. PubMed ID: 32591642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
    Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
    Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression.
    Janssens S; Burns K; Vercammen E; Tschopp J; Beyaert R
    FEBS Lett; 2003 Jul; 548(1-3):103-7. PubMed ID: 12885415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
    Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
    Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1.
    Smolinska MJ; Page TH; Urbaniak AM; Mutch BE; Horwood NJ
    J Immunol; 2011 Dec; 187(11):6043-51. PubMed ID: 22021612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT1 distinctively suppresses MyD88-depenedent and TRIF-dependent Toll-like receptor signaling in a kinase activity-independent manner.
    Zenke K; Muroi M; Tanamoto KI
    Cell Signal; 2018 Mar; 43():32-39. PubMed ID: 29242168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells.
    Endale M; Park SC; Kim S; Kim SH; Yang Y; Cho JY; Rhee MH
    Immunobiology; 2013 Dec; 218(12):1452-67. PubMed ID: 23735482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AP-1 activated by toll-like receptors regulates expression of IL-23 p19.
    Liu W; Ouyang X; Yang J; Liu J; Li Q; Gu Y; Fukata M; Lin T; He JC; Abreu M; Unkeless JC; Mayer L; Xiong H
    J Biol Chem; 2009 Sep; 284(36):24006-16. PubMed ID: 19592489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.